The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Danoprox     3-(4,5-diphenyl-1,3-oxazol-2- yl)propanoic...

Synonyms: Actirin, oxaprozin, Daypro, Dayrun, Deflam, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of oxaprozin

 

Psychiatry related information on oxaprozin

  • At week 6, oxaprozin treatment resulted in significantly greater improvement than placebo in physical functioning, role physical, and bodily pain (P < 0.05); social functioning, role emotional, and mental health (P < 0.01); and vitality and MCS score (P < 0.001) [6].
 

High impact information on oxaprozin

  • Panic disorder in a patient taking oxaprozin [7].
  • The effects of renal disease on the steady-state kinetics of oxaprozin were assessed in eight patients on hemodialysis with normal serum albumin levels and eight normal subjects who received six doses [2].
  • The mean total AUC, peak concentration, average steady-state plasma concentration, and trough concentration for total and unbound oxaprozin were decreased in the patients on hemodialysis [2].
  • The frequency of probably drug-related AST elevations was highest (5%) with aspirin; with oxaprozin, an investigational nonsteroidal antiinflammatory drug, the incidence (3%) fell between that for the other two agents [8].
  • The decreased plasma and tissue binding and lower Clint suggest that, in the treatment of azotemic patients with rheumatoid arthritis, the dose of oxaprozin should begin at 600 mg once a day [1].
 

Chemical compound and disease context of oxaprozin

  • This multicenter, 6-week, double-blind, placebo-controlled, parallel-group study compared the efficacy and safety of oxaprozin 1200 mg once daily with that of nabumetone 1000 mg once daily in patients with moderate-to-severe osteoarthritis (OA) of the knee [3].
  • CONCLUSIONS: As expected, once-daily oxaprozin proved to be as effective as diclofenac three times daily in reducing the primary efficacy variable of patient-assessed shoulder pain score in patients with periarthritis of the shoulder refractory to previous treatments with other NSAIDs [9].
  • A double-blind, parallel trial of oxaprozin versus naproxen in the treatment of osteoarthritis [10].
 

Biological context of oxaprozin

 

Anatomical context of oxaprozin

  • Substantial concentrations of oxaprozin are attained in synovial fluid, which is a proposed site of action for nonsteroidal anti-inflammatory drugs [12].
  • Studies were performed in rats and mice to investigate the mechanisms of the comparatively low irritancy in the gastrointestinal (GI) tract of oxaprozin, relative to that of other non-steroidal anti-inflammatory drugs [14].
  • A single dose of oxaprozin (100 mg/kg), given orally to rats, reduced the concentration of prostaglandin E2, but did not produce any gastric lesions or mucosal irritation, either visibly or when the mucosa was examined by scanning or transmission electronmicroscopy [14].
  • Gastroscopic evaluation of the effect of aspirin and oxaprozin on the gastric mucosa [15].
  • To evaluate the influence of indomethacin and oxaprozin on reproductive function in healthy young men, 34 volunteers with normal semen parameters were recruited [16].
 

Associations of oxaprozin with other chemical compounds

 

Gene context of oxaprozin

  • Studies have also shown oxaprozin to be effective therapy for juvenile rheumatoid arthritis and ankylosing spondylitis [21].
  • At week 2, the oxaprozin group showed significantly greater improvement than the placebo group in role physical, vitality, and mental component summary (MCS) scores (P < 0.05), and in physical functioning, bodily pain, social functioning, and physical component summary (PCS) scores (P < 0.01) [6].
  • Hydrolysis and rearrangement (isomerization by acyl migration) of oxaprozin glucuronide are greatly accelerated by plasma and human serum albumin [22].
 

Analytical, diagnostic and therapeutic context of oxaprozin

References

  1. Oxaprozin disposition in renal disease. Chiang, S.T., Morrison, G., Knowles, J.A., Ruelius, H.W., Walker, B.R. Clin. Pharmacol. Ther. (1982) [Pubmed]
  2. Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics. Audet, P.R., Knowles, J.A., Troy, S.M., Walker, B.R., Morrison, G. Clin. Pharmacol. Ther. (1988) [Pubmed]
  3. Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. Weaver, A., Rubin, B., Caldwell, J., McMahon, F.G., Lee, D., Makarowski, W., Offenberg, H., Sack, M., Sikes, D., Trapp, R. Clinical therapeutics. (1995) [Pubmed]
  4. Effects of oxaprozin alone or in combination with aspirin on hemostasis and plasma protein binding. Kahn, S.B., Hubsher, J.A. Journal of clinical pharmacology. (1983) [Pubmed]
  5. A case of Stevens-Johnson syndrome associated with oxaprozin therapy. Bell, M.J., Bishara, L.D. J. Rheumatol. (1998) [Pubmed]
  6. Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee. Zhao, S.Z., Dedhiya, S.D., Bocanegra, T.S., Fort, J.G., Kuss, M.E., Rush, S.M. Clinical therapeutics. (1999) [Pubmed]
  7. Panic disorder in a patient taking oxaprozin. Hough, D.W., Sellers, R., Cantilena, L.R. The American journal of psychiatry. (1995) [Pubmed]
  8. Hepatic safety of two analgesics used over the counter: ibuprofen and aspirin. Freeland, G.R., Northington, R.S., Hedrich, D.A., Walker, B.R. Clin. Pharmacol. Ther. (1988) [Pubmed]
  9. Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. Heller, B., Tarricone, R. Current medical research and opinion. (2004) [Pubmed]
  10. A double-blind, parallel trial of oxaprozin versus naproxen in the treatment of osteoarthritis. Ginsberg, F., Famaey, J.P. Current medical research and opinion. (1984) [Pubmed]
  11. Metabolism and kinetics of oxaprozin in normal subjects. Janssen, F.W., Jusko, W.J., Chiang, S.T., Kirkman, S.K., Southgate, P.J., Coleman, A.J., Ruelius, H.W. Clin. Pharmacol. Ther. (1980) [Pubmed]
  12. Clinical pharmacokinetics of oxaprozin. Davies, N.M. Clinical pharmacokinetics. (1998) [Pubmed]
  13. Effects of food on oxaprozin bioavailability. Chiang, S.T., Knowles, J.A., Hubsher, J.A., Ruelius, H.W., Walker, B.R. Journal of clinical pharmacology. (1984) [Pubmed]
  14. Comparative irritancy of oxaprozin on the gastrointestinal tract of rats and mice: relationship to drug uptake and effects in vivo on eicosanoid metabolism. Rainsford, K.D. Aliment. Pharmacol. Ther. (1988) [Pubmed]
  15. Gastroscopic evaluation of the effect of aspirin and oxaprozin on the gastric mucosa. Lanza, F.L., Hubsher, J.A., Walker, B.R. Journal of clinical pharmacology. (1981) [Pubmed]
  16. Indomethacin and oxaprozin lower seminal prostaglandin levels but do not influence sperm motion characteristics and serum hormones of young healthy men in a placebo-controlled double-blind trial. Knuth, U.A., Kühne, J., Crosby, J., Bals-Pratsch, M., Kelly, R.W., Nieschlag, E. J. Androl. (1989) [Pubmed]
  17. Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. Lapane, K.L., Spooner, J.J., Mucha, L., Straus, W.L. Journal of the American Geriatrics Society. (2001) [Pubmed]
  18. Interactions between oxaprozin glucuronide and human serum albumin. Wells, D.S., Janssen, F.W., Ruelius, H.W. Xenobiotica (1987) [Pubmed]
  19. Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib. Brinker, A., Nourjah, P. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. (2005) [Pubmed]
  20. Double-blind study on the interaction of oxaprozin with metoprolol in hypertensives. Halabi, A., Linde, M., Zeidler, H., König, J., Kirch, W. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (1989) [Pubmed]
  21. Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug. Miller, L.G. Clinical pharmacy. (1992) [Pubmed]
  22. Reactions of oxaprozin-1-O-acyl glucuronide in solutions of human plasma and albumin. Ruelius, H.W., Kirkman, S.K., Young, E.M., Janssen, F.W. Adv. Exp. Med. Biol. (1986) [Pubmed]
  23. Oxaprozin dose proportionality. Chiang, S.T., Lasseter, K.C., Fluck, E.R., Janssen, F.W., Leelavathi, D., Hubsher, J.A. Journal of clinical pharmacology. (1984) [Pubmed]
  24. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine. Fraser, A.D., Howell, P. Journal of analytical toxicology. (1998) [Pubmed]
  25. The effect of co-administered drugs on oxaprozin binding to human serum albumin. Aubry, A.F., Markoglou, N., Adams, M.H., Longstreth, J., Wainer, I.W. J. Pharm. Pharmacol. (1995) [Pubmed]
 
WikiGenes - Universities